Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open Phase Ib/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of HB0025 Injection Combined With Chemotherapy in Patients With Advanced Solid Tumor

NCT06758557 is registered in ClinicalTrials.gov with Huabo Biopharm Co., Ltd. as lead sponsor.

NCT NCT06758557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06758557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open Phase Ib/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of HB0025 Injection Combined With Chemotherapy in Patients With Advanced Solid Tumor
Lead sponsor
Huabo Biopharm Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 31, 2024
Completion date
February 28, 2026
Enrollment
282 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

advanced endometrial cancer, advanced nsclc